The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models
The treatment of ROS1-rearranged non-small cell lung cancer with the TKI crizotinib is limited due to the emergence of resistance. Here, the authors develop a new ROS1/NTRK inhibitor, DS-6051b, which overcomes crizotinib resistance in preclinical models.
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2019
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/1fb146a2c258459e81f631757ffb5a98 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:1fb146a2c258459e81f631757ffb5a98 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:1fb146a2c258459e81f631757ffb5a982021-12-02T14:38:58ZThe new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models10.1038/s41467-019-11496-z2041-1723https://doaj.org/article/1fb146a2c258459e81f631757ffb5a982019-08-01T00:00:00Zhttps://doi.org/10.1038/s41467-019-11496-zhttps://doaj.org/toc/2041-1723The treatment of ROS1-rearranged non-small cell lung cancer with the TKI crizotinib is limited due to the emergence of resistance. Here, the authors develop a new ROS1/NTRK inhibitor, DS-6051b, which overcomes crizotinib resistance in preclinical models.Ryohei KatayamaBo GongNoriko TogashiMasaya MiyamotoMasaki KigaShiho IwasakiYasuki KamaiYuichi TominagaYasuyuki TakedaYoshiko KagoshimaYuki ShimizuYosuke SetoTomoko Oh-haraSumie KoikeNaoki NakaoHiroyuki HanzawaKengo WatanabeSatoshi YodaNoriko YanagitaniAaron N. HataAlice T. ShawMakoto NishioNaoya FujitaTakeshi IsoyamaNature PortfolioarticleScienceQENNature Communications, Vol 10, Iss 1, Pp 1-12 (2019) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Science Q |
| spellingShingle |
Science Q Ryohei Katayama Bo Gong Noriko Togashi Masaya Miyamoto Masaki Kiga Shiho Iwasaki Yasuki Kamai Yuichi Tominaga Yasuyuki Takeda Yoshiko Kagoshima Yuki Shimizu Yosuke Seto Tomoko Oh-hara Sumie Koike Naoki Nakao Hiroyuki Hanzawa Kengo Watanabe Satoshi Yoda Noriko Yanagitani Aaron N. Hata Alice T. Shaw Makoto Nishio Naoya Fujita Takeshi Isoyama The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models |
| description |
The treatment of ROS1-rearranged non-small cell lung cancer with the TKI crizotinib is limited due to the emergence of resistance. Here, the authors develop a new ROS1/NTRK inhibitor, DS-6051b, which overcomes crizotinib resistance in preclinical models. |
| format |
article |
| author |
Ryohei Katayama Bo Gong Noriko Togashi Masaya Miyamoto Masaki Kiga Shiho Iwasaki Yasuki Kamai Yuichi Tominaga Yasuyuki Takeda Yoshiko Kagoshima Yuki Shimizu Yosuke Seto Tomoko Oh-hara Sumie Koike Naoki Nakao Hiroyuki Hanzawa Kengo Watanabe Satoshi Yoda Noriko Yanagitani Aaron N. Hata Alice T. Shaw Makoto Nishio Naoya Fujita Takeshi Isoyama |
| author_facet |
Ryohei Katayama Bo Gong Noriko Togashi Masaya Miyamoto Masaki Kiga Shiho Iwasaki Yasuki Kamai Yuichi Tominaga Yasuyuki Takeda Yoshiko Kagoshima Yuki Shimizu Yosuke Seto Tomoko Oh-hara Sumie Koike Naoki Nakao Hiroyuki Hanzawa Kengo Watanabe Satoshi Yoda Noriko Yanagitani Aaron N. Hata Alice T. Shaw Makoto Nishio Naoya Fujita Takeshi Isoyama |
| author_sort |
Ryohei Katayama |
| title |
The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models |
| title_short |
The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models |
| title_full |
The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models |
| title_fullStr |
The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models |
| title_full_unstemmed |
The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models |
| title_sort |
new-generation selective ros1/ntrk inhibitor ds-6051b overcomes crizotinib resistant ros1-g2032r mutation in preclinical models |
| publisher |
Nature Portfolio |
| publishDate |
2019 |
| url |
https://doaj.org/article/1fb146a2c258459e81f631757ffb5a98 |
| work_keys_str_mv |
AT ryoheikatayama thenewgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT bogong thenewgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT norikotogashi thenewgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT masayamiyamoto thenewgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT masakikiga thenewgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT shihoiwasaki thenewgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT yasukikamai thenewgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT yuichitominaga thenewgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT yasuyukitakeda thenewgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT yoshikokagoshima thenewgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT yukishimizu thenewgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT yosukeseto thenewgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT tomokoohhara thenewgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT sumiekoike thenewgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT naokinakao thenewgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT hiroyukihanzawa thenewgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT kengowatanabe thenewgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT satoshiyoda thenewgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT norikoyanagitani thenewgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT aaronnhata thenewgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT alicetshaw thenewgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT makotonishio thenewgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT naoyafujita thenewgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT takeshiisoyama thenewgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT ryoheikatayama newgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT bogong newgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT norikotogashi newgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT masayamiyamoto newgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT masakikiga newgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT shihoiwasaki newgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT yasukikamai newgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT yuichitominaga newgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT yasuyukitakeda newgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT yoshikokagoshima newgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT yukishimizu newgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT yosukeseto newgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT tomokoohhara newgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT sumiekoike newgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT naokinakao newgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT hiroyukihanzawa newgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT kengowatanabe newgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT satoshiyoda newgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT norikoyanagitani newgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT aaronnhata newgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT alicetshaw newgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT makotonishio newgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT naoyafujita newgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT takeshiisoyama newgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels |
| _version_ |
1718390759298695168 |